查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1786624

全球融合切片檢查市場

Fusion Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 277 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球融合切片檢查市場規模將達到 11 億美元

全球融合切片檢查市場規模預計在2024年達到7.146億美元，預計在分析期（2024-2030年）內將以6.7%的複合年成長率成長，到2030年將達到11億美元。經直腸切片檢查途徑是本報告分析的細分市場之一，預計其複合年成長率為5.5%，到分析期結束時將達到6.409億美元。經會陰切片檢查途徑細分市場在分析期間的複合年成長率預計為8.9%。

美國市場規模估計為 1.947 億美元，中國市場預計複合年成長率為 10.3%

美國融合切片檢查市場規模預計在2024年達到1.947億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到2.163億美元，在2024-2030年的分析期間內，複合年成長率為10.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.4%和6.4%。在歐洲，預計德國市場的複合年成長率為4.4%。

全球融合切片檢查市場－主要趨勢與促進因素摘要

融合切片檢查將如何徹底改變癌症診斷？

融合切片檢查因其卓越的準確性和精準定位可疑病變的能力，代表了癌症診斷，尤其是在前列腺癌檢測領域的突破性進展。與僅依賴經直腸超音波(TRUS) 成像的傳統切片檢查方法不同，融合切片檢查整合了磁振造影(MRI) 和即時超音波，從而增強了病變的可視化並提高了取樣準確性。這種組合顯著降低了假陰性結果和不必要重複切片檢查的風險，解決了癌症診斷中長期存在的難題。由於前列腺癌發生率不斷上升以及對早期準確檢測的需求，融合切片檢查正迅速被全球領先的醫院、癌症中心和診斷實驗室所採用。

醫療保健提供者日益意識到傳統切片檢查技術的局限性，這進一步推動了對MRI-超音波融合切片檢查的需求。當PSA（前列腺特異性抗原）水平升高，但標準的TRUS引導切片檢查尚無定論時，臨床醫生和研究人員擴大提倡使用MRI-超音波。此外，影像軟體和人工智慧驅動的診斷工具的進步提高了病變檢測的準確性，使融合切片檢查成為包括腎臟、肝臟和乳房惡性腫瘤在內的各種癌症更可靠的診斷工具。隨著精準醫療的不斷發展，融合切片檢查在早期癌症檢測和改善個人化治療方案中的作用日益凸顯。

科技如何使融合切片檢查更加準確和有效率？

醫學影像和切片檢查技術的最新創新顯著提高了融合切片檢查程序的效率和準確性。人工智慧影像分析增強了病變檢測能力，降低了取樣誤差的風險，並提高了診斷信心。即時3D成像進一步最佳化了切片檢查流程，使臨床醫生能夠精確定位腫瘤位置並相應地調整穿刺針軌跡。此外，機器人輔助切片檢查系統現已與融合切片檢查平台整合，以提高準確性，最大限度地減少患者不適，並縮短手術時間。

此外，雲端基礎切片檢查管理軟體的開發簡化了資料儲存、分析以及病理學家和腫瘤學家之間的遠端協作。這些數位平台實現了切片檢查結果的無縫共用，促進了多學科癌症治療和第二意見的諮詢。此外，機器學習演算法與融合切片檢查系統的整合實現了癌變組織的自動識別，減少了侵入性再次手術的需求。隨著微創診斷技術的不斷普及，融合切片檢查有望成為切片檢查診斷的標準，取代結果往往不明確或不可靠的傳統活體組織切片。

哪些醫學專業和醫療保健組織正在推動融合切片檢查的需求？

泌尿系統仍然是推動融合切片檢查需求的主要醫學專科，前列腺癌診斷佔其應用的大部分。領先的醫院、癌症診所和診斷影像中心正在積極投資融合切片檢查系統，以改善患者預後並降低誤診率。此外，學術研究和臨床試驗機構正在利用融合切片檢查技術探索新的生物標記並評估標靶治療，將其應用範圍擴展到標準癌症診斷之外。

除攝護腺癌外，融合切片檢查在腎病學、胃腸病學和肝病學領域也日益普及，用於檢測腎臟、肝臟和胰臟腫瘤。乳癌研究也受益於這項技術。當乳房X光攝影和超音波觀察不確定時，融合切片檢查可以更準確地進行組織取樣。遠端醫療和遠距離診斷的普及使得融合切片檢查專業知識更容易獲得，即使在醫療資源匱乏、專科腫瘤影像資源匱乏的地區也是如此。隨著癌症發病率的上升以及對先進診斷技術投資的不斷增加，預計跨多個醫學專業的融合切片檢查需求將大幅成長。

推動市場成長的關鍵因素有哪些？

融合切片檢查市場的成長受到多種因素的推動，包括影像技術的進步、癌症盛行率的上升以及對早期和精準診斷的日益重視。人工智慧輔助成像和機器人切片檢查系統的廣泛應用提高了手術效率，降低了取樣誤差，並改善了患者的預後。此外，遠端醫療和雲端基礎診斷平台的擴展使得全球醫療機構，尤其是在腫瘤學專業知識有限的地區，更容易獲得融合切片檢查。

融合切片檢查設備的監管核准以及新生物標記與診斷通訊協定的整合也推動了市場擴張。癌症診斷向微創化的轉變以及個人化醫療投資的不斷增加，進一步增強了對融合切片檢查的需求。此外，醫療設備製造商、研究機構和醫療保健提供者之間的合作正在加速下一代切片檢查系統的開發，以提高準確性、自動化程度和人工智慧主導的決策能力。隨著醫療保健系統持續重視早期癌症檢測，融合切片檢查預計將在未來的精準腫瘤學中發揮越來越重要的作用。

部分

切片檢查途徑（經直腸切片檢查途徑、經會陰切片檢查途徑）；最終用途（醫院最終用途、診斷中心最終用途、門診治療中心最終用途）

受訪公司範例

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP31101

Global Fusion Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Fusion Biopsy estimated at US$714.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Transrectal Biopsy Route, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$640.9 Million by the end of the analysis period. Growth in the Transperineal Biopsy Route segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$194.7 Million While China is Forecast to Grow at 10.3% CAGR

The Fusion Biopsy market in the U.S. is estimated at US$194.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Fusion Biopsy Market - Key Trends & Drivers Summarized

Why is Fusion Biopsy Revolutionizing Cancer Diagnostics?

Fusion biopsy has emerged as a groundbreaking advancement in cancer diagnostics, particularly in the detection of prostate cancer, due to its superior accuracy and ability to target suspicious lesions with precision. Unlike traditional biopsy methods, which rely solely on transrectal ultrasound (TRUS) imaging, fusion biopsy integrates magnetic resonance imaging (MRI) with real-time ultrasound to enhance lesion visualization and improve sampling accuracy. This combination significantly reduces the risk of false-negative results and unnecessary repeat biopsies, addressing a long-standing challenge in cancer diagnostics. Given the increasing prevalence of prostate cancer and the need for early and accurate detection, fusion biopsy is rapidly gaining adoption in leading hospitals, cancer centers, and diagnostic laboratories worldwide.

The growing awareness among healthcare providers about the limitations of conventional biopsy techniques has further fueled the demand for MRI-ultrasound fusion biopsy. Clinicians and researchers are increasingly advocating for its use in cases where PSA (prostate-specific antigen) levels are elevated but standard TRUS-guided biopsies yield inconclusive results. Additionally, advancements in imaging software and AI-driven diagnostic tools have enhanced the accuracy of lesion detection, making fusion biopsy a more reliable diagnostic tool for various forms of cancer, including kidney, liver, and breast malignancies. As precision medicine continues to evolve, the role of fusion biopsy in improving early cancer detection and personalized treatment planning is becoming more prominent.

How is Technology Enhancing the Accuracy and Efficiency of Fusion Biopsy?

Recent innovations in medical imaging and biopsy technology have significantly improved the efficiency and accuracy of fusion biopsy procedures. AI-powered image analysis has enhanced lesion detection capabilities, reducing the risk of sampling errors and improving diagnostic confidence. Real-time 3D imaging has further optimized the biopsy process by allowing clinicians to precisely map tumor locations and adjust needle trajectories accordingly. Additionally, robotic-assisted biopsy systems are being integrated with fusion biopsy platforms to increase precision, minimize patient discomfort, and reduce procedure time.

The development of cloud-based biopsy management software has also streamlined data storage, analysis, and remote collaboration among pathologists and oncologists. These digital platforms enable seamless sharing of biopsy results, facilitating multidisciplinary cancer care and second-opinion consultations. Moreover, the integration of machine learning algorithms into fusion biopsy systems is allowing for the automated identification of cancerous tissues, reducing the need for invasive repeat procedures. As the adoption of minimally invasive diagnostic techniques continues to grow, fusion biopsy is expected to become a standard of care in oncological diagnostics, replacing conventional biopsy methods that often yield inconclusive or unreliable results.

Which Medical Specialties and Healthcare Institutions Are Driving Demand for Fusion Biopsy?

Urology remains the primary medical specialty driving demand for fusion biopsy, as prostate cancer diagnosis accounts for the majority of its applications. Leading hospitals, specialty cancer clinics, and diagnostic imaging centers are actively investing in fusion biopsy systems to improve patient outcomes and reduce misdiagnosis rates. Additionally, academic research institutions and clinical trial organizations are utilizing fusion biopsy technology to study new biomarkers and evaluate targeted therapies, expanding its application beyond standard cancer diagnostics.

Beyond prostate cancer, the adoption of fusion biopsy is growing in nephrology, gastroenterology, and hepatology for the detection of kidney, liver, and pancreatic tumors. Breast cancer research is also benefiting from the technology, as fusion biopsy is enabling more precise tissue sampling in cases where mammographic and ultrasound findings are inconclusive. The expansion of telemedicine and remote diagnostics has further facilitated access to fusion biopsy expertise in underserved regions, where specialized oncological imaging was previously limited. With rising cancer incidence rates and increasing investments in advanced diagnostic technologies, the demand for fusion biopsy across multiple medical specialties is expected to surge.

What Key Factors Are Driving Market Growth?

The growth in the fusion biopsy market is driven by several factors, including advancements in imaging technology, increasing cancer incidence rates, and the growing emphasis on early and accurate diagnosis. The widespread adoption of AI-assisted imaging and robotic biopsy systems has improved procedural efficiency, reducing the likelihood of sampling errors and improving patient outcomes. Additionally, the expansion of telemedicine and cloud-based diagnostic platforms has made fusion biopsy more accessible to healthcare institutions worldwide, particularly in regions with limited oncological expertise.

Regulatory approvals for fusion biopsy devices and the integration of new biomarkers into diagnostic protocols are also fueling market expansion. The shift toward minimally invasive cancer diagnostics, coupled with rising investments in personalized medicine, has further strengthened the demand for fusion biopsy. Additionally, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating the development of next-generation biopsy systems that enhance precision, automation, and AI-driven decision-making. As healthcare systems continue to prioritize early cancer detection, fusion biopsy is expected to play an increasingly pivotal role in the future of precision oncology.

SCOPE OF STUDY:

The report analyzes the Fusion Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biopsy Route (Transrectal Biopsy Route, Transperineal Biopsy Route); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Ambulatory Care Centers End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Fusion Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Prostate Cancer Drives Adoption of Fusion Biopsy for Accurate Diagnosis
    • Advancements in MRI and Ultrasound Integration Technologies Throw the Spotlight on Precision Biopsy Tools
    • Increased Focus on Minimally Invasive and Targeted Diagnostics Supports Growth of Fusion Biopsy Procedures
    • Clinical Evidence Supporting Improved Cancer Detection Rates With MRI/US Fusion Enhances Physician Confidence
    • Surge in Adoption of MRI-Visible Lesion Mapping Enables High-Precision Prostate Sampling
    • Expansion of Urology Clinics and Specialty Diagnostic Centers Fuels Market Access and Adoption
    • Growth in Medicare and Private Reimbursement Coverage Supports Procedural Volume
    • Integration of AI and Image-Guided Navigation Enhances Fusion Biopsy Accuracy and Workflow
    • Rising Demand for Outpatient Biopsy Solutions Promotes Use of Office-Based Fusion Systems
    • Development of Robotic and Semi-Automated Fusion Platforms Supports Standardization of Results
    • Global Awareness Campaigns on Early Detection of Prostate Cancer Encourage Patient Screening
    • Improved Patient Comfort and Reduced Complication Rates Drive Preference for Fusion Over TRUS-Only Biopsies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fusion Biopsy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Transrectal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Transperineal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ambulatory Care Centers End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION